Perceptive Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,330,802 shares of the biopharmaceutical company’s stock after selling 138,000 shares during the quarter. Alnylam Pharmaceuticals makes up about 5.6% of Perceptive Advisors LLC’s holdings, making the stock its 4th biggest holding. Perceptive Advisors LLC owned 1.33% of Alnylam Pharmaceuticals worth $169,079,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Strs Ohio purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $141,000. CENTRAL TRUST Co grew its position in Alnylam Pharmaceuticals by 746.3% during the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,000 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $165,000. Segall Bryant & Hamill LLC purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $235,000. Finally, American International Group Inc. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $255,000. 92.44% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $133.02 on Monday. Alnylam Pharmaceuticals, Inc. has a one year low of $46.90 and a one year high of $147.63. The company has a market cap of $13,284.42, a P/E ratio of -24.59 and a beta of 2.67. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.02.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 6,249 shares of the stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the completion of the sale, the senior vice president now directly owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Michael Mason sold 36,745 shares of the stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.
Several equities analysts have issued reports on ALNY shares. Piper Jaffray Companies restated a “buy” rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 17th. BidaskClub cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. B. Riley restated a “buy” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, December 11th. Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research note on Friday, December 15th. Finally, Chardan Capital reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $126.76.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/12/alnylam-pharmaceuticals-inc-alny-is-perceptive-advisors-llcs-4th-largest-position.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.